drugset / Trial / NCT07195669

RCT: Suzetrigine vs Norco for Post-op Pain

NCT07195669

Phase 4 Not yet recruiting 76 enrolled Jacob Lensing
RandomizedParallel-groupDouble-blindTreatment

Summary

Journavx (suzetrigine) is a novel non-opioid analgesic that is FDA approved for acute pain management and may offer a promising alternative for managing postoperative pain. Suzetrigine is selective inhibitor of the sodium channel NaV1.8, for managing acute pain. NaV1.8, a sodium channel, plays a key role in transmitting pain signals. Importantly, this channel is minimally expressed in the brain, enabling effective pain control without the potential central nervous system side effects of respiratory depression and addiction associated with opioids. Clinical trials have shown Journavx to be effective in managing moderate to severe post-operative pain equal to that of opiates. This study aims to further evaluate the efficacy and safety of Journavx in managing post-operative pain after third molar removal and orthognathic surgery. Participants in this study should be aged 18-45 without significant autoimmune diseases, chronic kidney disease, liver disease, chronic pain disorder including temporomandibular joint disorder, bleeding disorders, pregnant or nursing, undergoing either extraction of both lower third molars or orthognathic surgery of both the maxilla and mandible.

Timeline

Start
2025-10-01
Primary completion
2025-12-30
Completion
2026-01-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydrocodone Unknown
Subject Suzetrigine Small molecule 50 mg Oral

Indications

No indication recorded.